Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cognite

- PMLiVE

Sanofi/Regeneron’s Dupixent successor underwhelms in phase 2

Success against placebo, but fails to outperform Dupixent

- PMLiVE

Regeneron’s bispecific for lymphoma works in CAR-T failures

Regeneron has reported positive results with its REGN1979 drug in patients with non-Hodgkin’s lymphoma, including the evidence it can work in patients who have previously tried CAR-T therapies.The new data...

- PMLiVE

Havas Lynx poem for charity has women’s interests at heart

Highlights overlooked cardiovascular risks

- PMLiVE

Havas Lynx launches Parkinson’s support website

Coincides with World Parkinson’s Day

- PMLiVE

Alnylam swaps Sanofi for Regeneron as R&D partner

Novel alliance between two biotechs

- PMLiVE

UK Biobank generates “largest open access resource of exome data”

Around 50,000 de-identifed genetic profiles available for research

- PMLiVE

Changing healthcare communications

Replacing anxiety with confidence, mediocrity with purpose

- PMLiVE

Havas Lynx Group scoops nine Golds at PM Society Awards

Sanofi Genzyme and Regeneron topped the pharma company charts

Sanofi reception

Sanofi and Regeneron re-jig immuno-oncology deal

Partners refocus around two promising bispecific candidates

- PMLiVE

Regeneron’s early stage bispecific shows promise

Bispecifics and antibody drug conjugates will challenge CAR-Ts

- PMLiVE

Havas Lynx launch clinical trial recruitment agency

And poaches Langland’s Mark Evans to lead the new offering

- PMLiVE

Havas Lynx and Aardman launch mental health animation

Releases the video for World Mental Health Day

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links